Hikma Pharmaceuticals Share Discussion Threads

[r ball] 20/8/2013 17:14

quite. bullish trading stmt.

[broadwood] 19/8/2013 18:51

Results upcoming.

[broadwood] 09/7/2013 13:21

Consolidating yesterday's gains.

[broadwood] 08/7/2013 14:40

Hikma Pharmaceuticals has jumped more than 6% after lifting its full year revenue forecast for the second time in just a couple of months
The company said it expected revenues to rise by 17% in 2013 thanks to strong sales of its antibiotic doxycycline. Previously it had forecast a 13% increase in May.

Its shares have added 57p to £10.51, helped by vague talk of possible merger activity in the sector. Meanwhile analyst Savvas Neophytou at Panmure Gordon said:


As a buyer of the stock, one takes windfalls with glee. We talked about the doxycycline windfall back in March when we speculated it could add an incremental $100m of profits this year. To that end, it is disappointing the company's guidance talks of only $60m or so of incremental profits so we will go against guidance and increase our forecasts by some 29% to 90.7c. Given the nature of windfalls (one-off and unpredictable), we make no changes to 2014 forecasts at this stage. We raise our target price to 1100p (1000p).

The stock is now trading at a prospective year PE ratio of 16.3 times (2013) and 14.9 times (2014). Although this is a significant premium to pan-European, large-cap pharmaceutical companies, we believe this is warranted due to its growth potential

[broadwood] 08/7/2013 07:43

Doing very nicely so far.

[broadwood] 08/7/2013 07:18

Hikma Pharmaceutical said all of its businesses have continued to perform well and overall it expects revenue to grow by around 17 per cent in 2013, up from previous guidance of around 13 per cent.

Across its main businesses, generics continued to benefit from strong doxycycline sales. Given the strong performance of doxycycline, Hikma said it is raising its full year guidance for this business to revenue of around $200m with a reported operating margin of above 30%.

Elsewhere its branded business remains on track to meet its current full year guidance of around 9% revenue growth or 11% in constant currency, with adjusted operating margin in line with 2012. Due to the timing of shipments, Branded revenue growth is expected to be stronger in the second half of the year, Hikma explained.

Its injectables business has performed well since its last update in May, driven by strong performances in the US and Europe. Hikma said there has been strong demand from the MENA region, where it has won some key tenders.

"We expect these tenders will drive MENA revenue growth in the second half of the year. We continue to expect the global injectables business to deliver low double digit revenue growth for the full year," the group said in a statement.

Chief Executive Officer Said Darwazah commented: "We are performing well across all of our businesses and I am pleased to be able to raise our group guidance for the full year once again."

"Overall, our diversified business model is positioning the group to deliver another strong year in 2013."

[broadwood] 08/7/2013 07:01

Bought some at the off.

[abcd1234] 01/3/2013 13:18

Lots on the wires about possible values for this part of the business ;O)

[northernlass] 21/5/2012 14:55

Will Surpass $1bn in Revenue

HIKMA REITERATES GUIDANCE DESPITE GENERICS HICCUPS

Things appear to be proceeding to plan at Hikma Pharmaceuticals as it has reiterated its revenue growth guidance for 2012, despite a few setbacks in its generic drugs business.

"We are making good progress towards delivering our targets for this year and surpassing the important milestone of $1bn in revenue," said Said Darwazah, Chief Executive Officer of Hikma.

The group announced 28% growth in its branded business during the first four months of the year, along with 12%organic revenue growth.

"Excellent" growth has been seen in two of the company's largest markets, Algeria and Egypt, which have benefited from increased local production and greater manufacturing capacity, respectively.

A slower-than-expected start in Sudan and the effect of reorganisation in Iraq has been partially offset by a good performance from its businesses in Saudi Arabia, Tunisia and Libya, as well as higher tender sales.

In a statement the company said: "We reiterate our guidance of around 20% Branded revenue growth for the full year and expect around 45% of revenue to be delivered in the first half.

"We continue to expect gross margin and adjusted operating margin in 2012 to be broadly in line with 2011, reflecting the increases that we anticipated in wages and research and development expense and the impact of consolidating Promopharm, our recent acquisition in Morocco. The benefit of operating leverage will mean margins are stronger in the second half of the year."

Divisionally, the firm's injectables business has performed "extremely well" this year, driving strong demand for its products in the US. Overall, the group expects that the global business will achieve revenue growth of more than 35% in 2012, with an adjusted operating margin in the high teens.

The Generics business, however, continues to see pricing pressures and revenue has been further affected by actions the company is taking in response to the US Food and Drug Administration (FDA) warning letter it received in February for its Eatontown facility, which is causing a slow-down in sales, but a stronger second half is expected. The full year adjusted earnings before interest and tax margin is set to be in the mid single-digits.

Source:



P.S.

Here's a couple of links about SCLP, one of the hottest stocks at the moment:

[volsung] 03/5/2012 10:10

is good yes?

[volsung] 02/5/2012 15:26

Naace on bad day.

[volsung] 30/4/2012 08:55

But I is and I like it. Bum bum boobies!!

[volsung] 26/4/2012 15:33

There does not be anybody here.

[aimshares] 03/10/2011 19:54

A big pharma will licence there drugs or will do a takeover of Verona pharma listed on Aim.

[odys2] 14/9/2011 08:48

Bouncing from 550 and this could be buying opp but for the very brave only as the troubles in Libya, Egypt, Syria and Middle East may still affect the possible recovery. There is an article in The Telegraph today titled "Libya and Egypt unrest hurts Hikma Pharmaceuticals". Worth reading.


Nevertheless looks like a possibility of a double bottom to me and worth trying with the stop around 530.

[chc15] 03/8/2011 09:20

been battered - buying opp now?

[odys2] 13/6/2011 12:02

I am out as planned.

[odys2] 13/6/2011 11:15

Does anybody know why the recent drop on quite high volume? Seems to me that there is no obvious reason. Nevertheless I am going to do a runner if the share price goes below the expected support at 800.

[nellie1973] 18/3/2011 18:41

Broker upgrade today